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SObjective: Resection of locally advanced non–small cell lung cancer using circulatory bypass is not frequently
performed. The objective of this study was to systematically review the long-term survival associated with the
published studies dealing with the performance of lung resections for non–small cell lung cancer using circu-
latory bypass.
Methods:A systematic review of publications dealing with lung resections for non–small cell lung cancer under
circulatory bypass spanning from January 1, 1990, to December, 31 2010, was performed using a PubMed search
with specific inclusion and exclusion criteria. The primary end point collected was survival. Several other clin-
ical variables were also collected and analyzed. Survival curves were calculated using the Kaplan–Meier
method. Univariate comparisons of survival were performed using a Cox proportional hazard model. Multivar-
iate analysis was carried out using a Cox regression model.
Results: The search algorithm yielded 20 articles for the analysis. The overall 5-year survival was 37% (median,
36  6 months). Survival was significantly higher when placement on bypass was planned (54%; median, 67
19 months) as opposed to unplanned or emergency placement (11%; median, 19  6 months; P ¼ .006). Mul-
tivariate analysis demonstrated that the use of unplanned bypass was prognostic for a worse long-term survival
(hazard ratio¼ 0.28; 95% confidence interval, 0.09–0.90; P¼ .033). The 30-day and 90-day perioperative mor-
talities were 0% and 1%, respectively.
Conclusions: The literature over the past 2 decades demonstrates that favorable long-term survival for extended
resections of locally advanced non–small cell lung cancer using circulatory bypass can be achieved. The use of
unplanned cardiopulmonary bypass, though, seems to be prognostic of unfavorable long-term survival.
(J Thorac Cardiovasc Surg 2011;142:1137-42)Despite technical advances in extracorporeal circulatory sup-
port, lung resections for advanced thoracic malignancies un-
der circulatory bypass (CPB) are relatively uncommon. The
underuse of CPB may reflect the reluctance among surgeons
to embrace an aggressive approach because of concerns of an
inevitable poor prognosis or fears of CPB-induced tumor dis-
semination.Theobjective of this reviewwas to systematically
review the long-term survival associated with published lung
resections for non–small cell lung cancer (NSCLC) per-
formed using CPB.MATERIALS AND METHODS
Search Strategy
A systematic search was performed using the PubMed database to iden-
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The Journal of Thoracic and Cararticles, case series, and individual reports from January 1, 1990, to Decem-
ber 31, 2010, were considered. Inclusion criteria were publications that de-
scribed resections requiring CPB support for an intent-to-cure resection.
Publications were excluded if the central focus of the study involved (1)
combined cardiac-pulmonary procedures, that is, resections performed un-
der CPB primarily for a cardiac procedure with a concomitant pulmonary
resection; and (2) lesions involving the carina necessitating a carinal resec-
tion. Exceptions to these included publications in which a minority of the
indications for CPB included carinal resections in a larger series.
A Boolean search strategy using the search term ‘‘non–small cell lung
cancer’’ identified 32,970 articles, and ‘‘cardiopulmonary bypass’’ identi-
fied 27,491 articles (Figure 1). A combined search revealed 18 publica-
tions. ‘‘Lung cancer’’ identified 191,888 articles and ‘‘circulatory
bypass’’ scored 12,099 hits. A combined search identified 32 articles. A
combination of ‘‘cardiopulmonary bypass’’ and ‘‘lung cancer’’ had the
highest yield of 209 articles. After reviewing the titles and, when appropri-
ate, the abstract or actual articles, 17 articles were selected for further re-
view, and the rest were rejected for meeting the exclusion criteria. Four
additional articles were identified from the references of these studies
and included for full review. These articles were then reviewed thoroughly
for completeness of information and to exclude any duplicity in publica-
tion, as was the case in 1 article. Ultimately, 20 articles1-20 were used for
the analysis (Figure 1, Table 1).
Variables Recorded and Evaluated
The primary end point collected was survival. Several clinical data were
also collected, including age, gender, organ resected, histology, pathologic
T status, pathologic N status, tumor stage, bypass type, planned bypass, use
of induction therapy, surgical approach, resection type, use of adjuvantdiovascular Surgery c Volume 142, Number 5 1137
Abbreviations and Acronyms
CPB ¼ circulatory bypass
NSCLC ¼ non–small cell lung cancer
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Stherapy, and start and end of the study period. The organ involvement
prompting the resection under CPB included the aorta, left atrium/pulmo-
nary veins, pulmonary arteries, and right atrium/inferior and superior vena
cava complex.
When collected and analyzed, the clinical variables were assigned cat-
egoric values for the purposes of comparison. For data that were numeric,
the variables were dichotomized on the basis of their mean values.
Although an extended effort was made to abstract the variables from
each of the publications reviewed, all of the variables were not universally
provided in each article. Because of the presence of unavailable data during
the abstraction process, an arbitrary cutoff of 70%was selected to establish
a minimum amount of information that was thought to be reasonable to en-
ter into the analysis. The 70% cutoff was chosen because it was thought
that this figure would allow for the authors to report generalizable results.
Of note, this cutoff seemed to be a natural break in the data that were pro-
vided (Table 2). Ultimately, CPB time, achievement of an R0 resection, and
adjuvant chemotherapy or radiation therapy were excluded from the
analysis.
Statistical Analysis
Survival curves based on the clinical data collected were calculated us-
ing the Kaplan–Meier method. Univariate comparison of survivals between
the grouped variables within specific clinical data was performed using
a Cox proportional hazard model. Multivariate analysis was carried out us-
ing a Cox regression model. The study characteristics that were analyzed
were selected from those variables in the univariate analysis that achieved
a P value of less than .1. We used bootstrapping, a resampling technique, to
verify the model used in the multivariate analysis.We generated 1000 boot-
strap samples while retaining the censoring percentage as in the observed
dataset. The significance of the 3 variables was reassessed on the basis of
the estimates obtained from the bootstrap. Statistical analysis was per-
formed using the statistical package R, version 2.10.1.
No formal analysis of study quality or publication bias was performed.
There was no formal funding source for this study. The authors had com-
plete control of the search, data analysis, and writing. No other individuals
were involved.RESULTS
Patient Characteristics
There were 72 patients identified with a mean age of 55
10 years. In 65 patients, the majority of examined variables
were obtained. Therewere 15 female patients (21%) among
the 71 patients for whom gender was reported.
A summary of the clinical data recorded is listed in Table
3. Stage information was provided for 70 patients. The ma-
jority of patients (84%) had stage IIIB, and the aorta was
the most commonly resected organ (43%). One third of
the patients had squamous carcinoma. There were 31 of
58 patients (53%) who received some form of induction
therapy. Pneumonectomy was the most commonly per-
formed resection (74%). There were 27 of 49 patients
(55%) who had any adjuvant therapy.1138 The Journal of Thoracic and Cardiovascular SurUnivariate Analysis
Univariate analysis was possible for 71 patients (Table 4).
For this entire cohort, the 5-year survival was 37% (median
survival, 36 6 months) (Figure 2). A planned CPBwas as-
sociated with a significantly higher survival than an un-
planned/emergency placement of the patient on bypass
(P¼ .006) (Figure 3). Aortic resection had a better survival,
albeit nonsignificantly, compared with other mediastinal or-
gans (P ¼ .065). Publications after 2004 reported a nonsig-
nificantly higher survival than earlier publications
(P ¼ .062). The remainder of the clinical variables—the
type of CPB (routine vs femoro-femoral vs passive aorta
to aorta shunt), histology (nonsquamous vs squamous), in-
duction therapy vs none, and type of incision (thoracotomy
vs sternotomy)—did not demonstrate significantly different
survivals.
Multivariate Analysis
A multivariate analysis (n ¼ 52) was performed analyz-
ing 3 variables: organ resected (aorta vs other), CPB
(planned vs unplanned), and publication year (before
2004 vs after 2004). Multivariate analysis revealed that sur-
vival was significantly lower for an unplanned/emergency
placement of the patient on bypass compared with a planned
CPB (P¼ .033) (Table 5), although the significancewas lost
after bootstrap evaluation (P ¼ .072) (Table 6).
Perioperative Mortality
The incidences of 30-day and 90-day perioperative mor-
tality were 0% and 1%, respectively.
DISCUSSION
Lung cancers involving vital mediastinal vascular struc-
tures are often considered high risk for resection and
thought to be associated with a poor prognosis. Martini
and colleagues21 observed a 19% 5-year survival for pa-
tients with T3 and T4 lesions with mediastinal involvement
when excluding those patients with N2 disease, whereas
a more recent study observed a 34.8% 5-year survival for
patients with T4 lesions managed surgically.22 Few reports
exist in the western literature detailing their resection using
circulatory support, and our analysis of these studies raises
some interesting results.
Favorable Survival With Circulatory Bypass,
Particularly in a Planned Setting
Despite 84% of the patients having stage IIIB disease
and 82% of lesions being classified as T4, the overall
5-year survival was a remarkable 37% (median survival,
36  6 months). Survival was significantly higher when re-
sections were performed under CPB in a planned, non-
emergency setting.
In contrast, the reported 5-year survival for stage IIIB
NSCLC is 3% to 7%with a median survival of 13.7 monthsgery c November 2011
FIGURE 1. Search algorithm.
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ation therapy alone.23 A phase II trial exploring surgery af-
ter chemoradiation for stage IIIA (N2) and IIIB disease
observed an overall 3-year survival of 24%.24 Only 40%
of patients had stage IIIB disease, and this group had a me-
dian survival of 19 months.Histology Not Significant in Resection Using
Circulatory Bypass
Most of the NSCLCs invading mediastinal structures are
by definition central, with few exceptions. Squamous cellTABLE 1. Studies used in the systematic review analysis
First author Year of publication
No. of patients obtained
from study
Kodama1 1990 2
Shirakusa2 1991 4
Horita3 1993 2
Ricci4 1994 2
Okubo5 1996 1
Ernst6 1999 1
Sugio7 1999 1
Klepetko8 1999 4
Ferguson9 2000 1
Vaporciyan10 2002 1
Hasegawa11 2003 11
Baron12 2003 4
Byrne13 2004 7
de Perrot14 2005 7
Ohta15 2005 13
Wiebe16 2006 3
Nomori17 2005 1
Shiraishi18 2005 5
Vojacek19 2006 1
Shimizu20 2010 1
The Journal of Thoracic and Carcancers are more commonly central lesions compared
with non-squamous lesions. In our analysis, squamous car-
cinomas did not prove more lethal compared with non-
squamous lesions. This finding was contrary to some21
and similar to other studies of surgical resection in locally
advanced cancers where the histology was not a significant
prognostic factor.22,25Organ Resected Less Important Than Other Factors
Aside from histology, other factors were important in
predicting improved survival using CPB. The organ re-
sected was not one of these factors, as Yildizeli andTABLE 2. Availability of data for total number of patients included
(n ¼ 72)
Clinical variable % For whom data available (n)
Organ resected 100 (72)
CPB type 100 (72)
Year of publication 100 (72)
Pathologic T status 99 (71)
Surgical approach 99 (71)
Tumor stage 97 (70)
Histology 94 (68)
Age 93 (67)
Pathologic N status 90 (65)
Gender 88 (63)
Use of induction therapy 82 (59)
Resection type 74 (53)
Use of planned CPB 74 (53)
Use of adjuvant radiation therapy 60 (43)
Use of adjuvant chemotherapy 56 (40)
Performance of an R0 resection 47 (34)
CPB time 40 (29)
Values given in italics represent those variables for which<70% of the data were
available and, therefore, not analyzed.
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TABLE 3. Clinical variables
Stage (n ¼ 70)
IB 1 (1.4%)
IIA 3 (4.2%)
IIB 4 (6%)
IIIA 1 (1.4%)
IIIB 59 (84%)
IV 2 (3%)
Organ resection (n ¼ 72)
Aorta 31 (43%)
Left atrium/pulmonary veins 18 (25%)
Pulmonary artery 8 (11%)
SVC/IVC/right atrial complex 2 (3%)
Trachea 2 (3%)
Other organs 3 (4%)
>1 organ 8 (11%)
Histology (n ¼ 72)
Squamous 32 (37%)
Nonsquamous 40 (63%)
Adenocarcinoma 27
Large cell carcinoma 11
Other 2
Induction therapy (n ¼ 58) 31 (53%)
Chemotherapy 12
Radiation therapy 5
Chemoradiation therapy 14
Resections (n ¼ 53)
Pneumonectomy 39 (74%)
Lobectomy 13 (24%)
Bilobectomy 1 (2%)
Adjuvant therapy (n ¼ 49) 27 (55%)
Chemotherapy 15
Radiation therapy 10
Chemoradiation therapy 2
SVC, Superior vena cava; IVC, inferior vena cava.
TABLE 4. Univariate analysis
N
% 5-y
survival Median survival P
Organ resected (aorta vs
other)
71 49 vs 19 58  17 vs 25  5 .065
Age (>56 vs 56 y) 66 33 vs 30 37  9 vs 34  8 .940
Gender (M vs F) 62 33 vs 26 38  8 vs 31  12 .927
Histology (squamous vs
non-squamous)
67 23 vs 39 28  7 vs 45  11 .140
pT status (4 vs other) 70 25 vs 48 30  6 vs 57  22 .653
pN status (N0 vs N1þN2) 64 44 vs 17 50  13 vs 23  5 .209
Stage (IIIA vs IIIB) 69 52 vs 24 64  29 vs 29  5 .650
Bypass type (CPB vs other) 71 23 vs 47 29  6 vs 55  17 .355
Induction therapy (no vs
other)
59 34 vs 32 39  10 vs 36  9 .820
Surgical approach
(thoracotomy vs other)
70 26 vs 42 30  6 vs 49  15 .346
Resection (lobe vs
pneumonectomy)
52 29 vs 17 34  15 vs 24  5 .244
Planned CPB (yes vs no) 52 54 vs 11 67 19 vs 19  6 .006
Study start (2004 vs
<2004)
71 47 vs 14 55  14 vs 21  5 .062
FIGURE 2. Overall survival.
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studies by Fukuse and colleagues,26 who found a lower sur-
vival with left atrial invasion compared with great vessel in-
volvement, and Pitz and colleagues,25 who also observed
better survival with great vessel involvement compared
with other mediastinal structures. However, individual stud-
ies of organ resection show similar survivals. Studies of left
atrial resections have reported 5-year survivals in the range
of 14% to 16%,27,28 with an earlier study having obtained
a 22% 4-year survival, but that included T3 lesions and
stage IIIA disease.29 Venuta and colleagues30 observed
a similar 19% 5-year survival among their cohort of re-
sected patients with stage IIIB and pulmonary artery in-
volvement. A large study of superior vena cava resection
showed a 21% 5-year survival.31 The exception was the
study by Misthos and colleagues.32 Their small population
of patients with aortic resections showed a high 5-year sur-
vival of 30.7%, but Misthos and colleagues included pa-
tients in whom only the parietal pleura overlying the aorta
was involved. Such lesions involving only the adventitia1140 The Journal of Thoracic and Cardiovascular Surof the thoracic aorta could be classified as T3 and not T4,
per Grunenwald.33 The overall picture emerging from these
studies in which resections were performed without CPB
seems to be congruent with our observation that there is
no significant survival difference based on the specific or-
gan resected.
Lymph Node Status Not Important in Predicting
Survival in Circulatory Bypass Cohort
A substantial amount of clinical research has been de-
voted to the impact of lymph node status with respect togery c November 2011
FIGURE 3. Survival stratified by use of planned versus unplanned bypass.
CPB, Circulatory bypass.
TABLE 6. Multivariate analysis with bootstrap
No. Hazard ratio [95% CI] P
Organ resected (aorta vs
other)
26 vs 26 1.11 [0.31–4.59] .879
Planned bypass (yes vs no) 40 vs 12 0.28 [0.06–0.97] .072
Study start (2004 vs<2004) 38 vs 14 0.58 [0.21–1.50] .306
CI, Confidence interval.
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amore advanced lymphnode status has been found to be pre-
dictive of worse long-term survival34 as is the number sam-
pled35 and found positive.36 The findings of this systematic
review are contrary to these findings in that the nodal status
(N0 vs N1–2) was not predictive of a better or worse sur-
vival. This is in contrast with other studies7,9 and the study
by Doddoli and colleagues,37 who observed a difference in
median survival of 16 versus 9 months comparing N0–1
with N2 disease in NSCLC invading mediastinal structures.
Bernard and colleagues38 also observed a significantly lower
survival among T4 cancers invading mediastinal structures
when both the superior and inferior mediastinal nodes
were involved. The lack of an adequate sample size may
have affected the power of our study, explaining the above
findings. The other limitation is that theremay be a reporting
bias in the studies we gleaned from the literature.Study Limitations
Although publication bias was not formally evaluated,
there must be a strong bias to present the successful resec-
tions rather than those that ended suboptimally. This is evi-
denced by the outstanding survival in a population ofTABLE 5. Multivariate analysis
No. Hazard ratio [95% CI] P
Organ resected (aorta vs
other)
26 vs 26 1.11 [0.34–3.67] .863
Planned bypass (yes vs no) 40 vs 12 0.28 [0.09–0.90] .033
Study start (2004 vs<2004) 38 vs 14 0.58 [0.23–1.45] .243
CI, Confidence interval.
The Journal of Thoracic and Carpatients statistically known to have poor survival. Perhaps
more than survival, the extremely low perioperative mortal-
ity rate suggests that the group of patients presented in the
literature may represent a skewed population. The message,
however, is that successful complete resections can be per-
formed in carefully selected scenarios using CPB support.
Another limitation of this study is associated with the use
of limited data for analysis given the incompleteness of the
data provided in the articles reviewed. Also, most of the
case reports/series had 5 or fewer patients. Nevertheless,
an attempt was made to only evaluate those clinical vari-
ables for which 70% of the data from the aggregate group
of patients were provided. Although the study was perhaps
not as statistically stringent as is normally performed, we
think it was a reasonable attempt to achieve a certain level
of robustness to the data.
Last, this study included patients who underwent less
than full CPB, thereby introducing some heterogeneity
into the patients analyzed. Nevertheless, this may have
been justified because this does not diminish the fact that
a substantial operation was performed that required some
form of adjunct circulatory support, which is not physiolog-
ically experienced during routine resections. Furthermore,
this fact also does not diminish the theoretically detrimental
effect of circulating tumor cells via extracorporeal support,
a modality that intuitively would be to contribute to worse
long-term outcomes secondary to fostering metastasis,39 al-
though such an occurrence has been contested.40,41 Along
similar lines, a minority of patients had less than stage III
disease; therefore, there was heterogeneity in expected
survival, perhaps weighting it toward a more favorable
outcome. It certainly could be argued that adding those
patients who underwent simultaneous cardiac and
pulmonary operations for cardiac disease and malignancy
may have served as a comparison group for both of these
latter 2 issues, but this was outside the scope of this review.CONCLUSIONS
Our study points to a favorable outcome for locally ad-
vanced NSCLC when an extended resection is undertaken
under CPB in well-chosen candidates. A planned use of
a true CPB seemed to provide the best benefit. These favor-
able outcomes, however, must be interpreted with some
caution because they are based on a unique subset of pa-
tients with NSCLC.diovascular Surgery c Volume 142, Number 5 1141
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